Utilizing integrated bioinformatic, in vivo, and in vitro approaches, we have revealed the inflammatory profile of the chronically diseased kidney in diabetes and how SGLT2 inhibitor dapagliflozin could ameliorate DKD. Here, SLC5A2 is linked to diabetic kidney disease.